Transcranial photobiomodulation on acute & subacute stroke patients

The limited time for a therapeutic window of intravenous thrombolysis have been a problem since it’s approval twenty eight years ago. The availability of a stroke team for thrombectomy or intravenous thrombolysis, and the complexity of the eligibility criteria may be factors that can limit it’s use. Transcranial Laser Photobiomodulation is a novel treatment which can be offered safely to an acute and subacute stroke patient due to lack of adverse effects. Here, we present a small series of acute and subacute stroke patients who received photobiomodulation treatment during the first 72 hours followed by frequent consecutive treatment. Clinical improvement on the clinical neurological deficit and partial brain lesion resolution on MRI was observed. Acute and subacute stroke patients may benefit of transcranial photobiomodulation therapy with laser as observed clinically and on neuroimaging.